Roche: AI to enrich cancer diagnostics
(CercleFinance.com) - Roche announced on Monday that it has enriched its cancer diagnostics platform by adding some twenty new AI-related functionalities developed in collaboration with eight of its partners.
The Swiss biopharmaceutical group says that all these algorithms have been integrated within navify, its clinical evaluation software for oncology care teams.
Among these third-party applications are the 'Deep Bio' prostate cancer diagnostic device, DiaDeep's technology for accurately predicting breast cancer prognosis, and Mindpeak's AI tool for quantifying PD-L1 biomarkers present in many cancers.
The navify platform will also host Owkin's algorithm to identify the fastest and most effective treatment for colorectal cancer patients.
Solutions from Sonrai Analytics (microsatellite instability in colorectal cancer) and Stratipath (invasive breast cancer risk profile identification) will also enhance its diagnostic service.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The Swiss biopharmaceutical group says that all these algorithms have been integrated within navify, its clinical evaluation software for oncology care teams.
Among these third-party applications are the 'Deep Bio' prostate cancer diagnostic device, DiaDeep's technology for accurately predicting breast cancer prognosis, and Mindpeak's AI tool for quantifying PD-L1 biomarkers present in many cancers.
The navify platform will also host Owkin's algorithm to identify the fastest and most effective treatment for colorectal cancer patients.
Solutions from Sonrai Analytics (microsatellite instability in colorectal cancer) and Stratipath (invasive breast cancer risk profile identification) will also enhance its diagnostic service.
Copyright (c) 2024 CercleFinance.com. All rights reserved.